Marie-Pierre DubÃ©

List of Publications by Year
in descending order

209 papers	13,846 citations	34105 52 h-index	23533 111 g-index
225 all docs	225 docs citations	225 times ranked	22486 citing authors

#	Article	IF	Citations
1	Predictive risk factors for hospitalization and response to colchicine in patients with COVID-19. International Journal of Infectious Diseases, 2022, 116, 387-390.	3.3	2
2	Construction of a femininity score in the UK Biobank and its association with angina diagnosis prior to myocardial infarction. Scientific Reports, 2022, 12, 1780.	3.3	3
3	Leveraging large observational studies to discover genetic determinants of drug concentrations: A proofâ€ofâ€concept study. Clinical and Translational Science, 2022, 15, 1063-1073.	3.1	7
4	OUP accepted manuscript. Nucleic Acids Research, 2022, , .	14.5	1
5	Adenylate cyclase type 9 antagonizes cAMP accumulation and regulates endothelial signaling involved in atheroprotection. Cardiovascular Research, 2022, , .	3.8	3
6	Low-dose colchicine and high-sensitivity C-reactive protein after myocardial infarction: A combined analysis using individual patient data from the COLCOT and LoDoCo-MI studies. International Journal of Cardiology, 2022, 363, 20-22.	1.7	5
7	Including diverse and admixed populations in genetic epidemiology research. Genetic Epidemiology, 2022, 46, 347-371.	1.3	11
8	Colchicine for Secondary Prevention of Cardiovascular Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Canadian Journal of Cardiology, 2021, 37, 776-785.	1.7	68
9	Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). European Heart Journal Quality of Care & Clinical Outcomes, 2021, 7, 486-495.	4.0	44
10	Population Pharmacokinetics of Candesartan in Patients with Chronic Heart Failure. Clinical and Translational Science, 2021, 14, 194-203.	3.1	3
11	The associations of hostility and defensiveness with telomere length are influenced by sex and health status. Biology of Sex Differences, 2021, 12, 2.	4.1	8
12	Comparative effectiveness and safety of highâ€dose rivaroxaban and apixaban for atrial fibrillation: A propensity scoreâ€matched cohort study. Pharmacotherapy, 2021, 41, 379-393.	2.6	5
13	Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality. European Heart Journal, 2021, 42, 1742-1756.	2.2	63
14	Genetic meta-analysis of cancer diagnosis following statin use identifies new associations and implicates human leukocyte antigen (HLA) in women. Pharmacogenomics Journal, 2021, 21, 446-457.	2.0	4
15	Pharmacogenomics of the Efficacy and Safety of Colchicine in COLCOT. Circulation Genomic and Precision Medicine, 2021, 14, e003183.	3.6	7
16	Role of Adenylate Cyclase 9 in the Pharmacogenomic Response to Dalcetrapib. Circulation Genomic and Precision Medicine, 2021, 14, e003219.	3.6	4
17	Genetics of symptom remission in outpatients with COVID-19. Scientific Reports, 2021, 11, 10847.	3.3	7
18	Multitrait GWAS to connect disease variants and biological mechanisms. PLoS Genetics, 2021, 17, e1009713.	3.5	16

#	Article	IF	Citations
19	Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial. Lancet Respiratory Medicine,the, 2021, 9, 924-932.	10.7	218
20	Shared genetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions of effect. Nature Genetics, 2021, 53, 128-134.	21.4	155
21	A sex-specific evolutionary interaction between ADCY9 and CETP. ELife, 2021, 10, .	6.0	8
22	Comparative Effectiveness and Safety of Low-Dose Oral Anticoagulants in Patients With Atrial Fibrillation. Frontiers in Pharmacology, 2021, 12, 812018.	3.5	4
23	Oral Anticoagulant Prescription Trends, Profile Use, and Determinants of Adherence in Patients with Atrial Fibrillation. Pharmacotherapy, 2020, 40, 40-54.	2.6	83
24	A genetic model of ivabradine recapitulates results from randomized clinical trials. PLoS ONE, 2020, 15, e0236193.	2.5	3
25	Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). European Heart Journal, 2020, 41, 4092-4099.	2.2	174
26	A genetic association study of heart failure: more evidence for the role of BAG3 in idiopathic dilated cardiomyopathy. ESC Heart Failure, 2020, 7, 4384-4389.	3.1	11
27	High-sensitivity C-reactive protein is associated with clonal hematopoiesis of indeterminate potential. Blood Advances, 2020, 4, 2430-2438.	5.2	54
28	CYP2D6 polymorphism and its impact on the clinical response to metoprolol: A systematic review and metaâ€analysis. British Journal of Clinical Pharmacology, 2020, 86, 1015-1033.	2.4	30
29	Heritability of 596 lipid species and genetic correlation with cardiovascular traits in the Busselton Family Heart Study. Journal of Lipid Research, 2020, 61, 537-545.	4.2	29
30	Study design of Dal-GenE, a pharmacogenetic trial targeting reduction of cardiovascular events with dalcetrapib. American Heart Journal, 2020, 222, 157-165.	2.7	21
31	Spironolactone metabolite concentrations in decompensated heart failure: insights from the ATHENAâ€HF trial. European Journal of Heart Failure, 2020, 22, 1451-1461.	7.1	12
32	Statin Initiation: Guideline Concordance and Characteristics of New Users in Quebec, Canada. Canadian Journal of Clinical Pharmacology, 2020, 27, e69-e77.	1.1	1
33	Abstract 15518: Impact of Menopause on Cardiovascular Risk Factors Among Women Without Cardiovascular Disease: Insights From the CARTaGENE Study. Circulation, 2020, 142, .	1.6	0
34	A genetic model of ivabradine recapitulates results from randomized clinical trials. , 2020, 15, e0236193.		0
35	A genetic model of ivabradine recapitulates results from randomized clinical trials. , 2020, 15, e0236193.		0
36	A genetic model of ivabradine recapitulates results from randomized clinical trials. , 2020, 15, e0236193.		0

#	Article	IF	Citations
37	A genetic model of ivabradine recapitulates results from randomized clinical trials. , 2020, 15, e0236193.		0
38	LONG-TERM RESIDUAL RISK AND PREDICTORS OF CARDIOVASCULAR DISEASE IN INDIVIDUALS TAKING STATINS FOR PRIMARY PREVENTION: INSIGHTS FROM THE CARTAGENE STUDY. Journal of the American College of Cardiology, 2019, 73, 1773.	2.8	0
39	rs73185306 C/T Is Not a Predisposing Risk Factor for Inherited Chromosomally Integrated Human Herpesvirus 6A/B. Journal of Infectious Diseases, 2019, 221, 878-881.	4.0	1
40	Meta-analysis of Randomized Controlled Trials Assessing the Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies on Mortality and Cardiovascular Outcomes. American Journal of Cardiology, 2019, 124, 1869-1875.	1.6	15
41	Validation of Genome-Wide Polygenic Risk Scores for Coronary Artery Disease in French Canadians. Circulation Genomic and Precision Medicine, 2019, 12, e002481.	3.6	59
42	Increasing Dietary Vitamin K Intake Stabilizes Anticoagulation Therapy in Warfarin-Treated Patients with a History of Instability: A 24-week Randomized Controlled Trial (OR36-04-19). Current Developments in Nutrition, 2019, 3, nzz035.OR36-04-19.	0.3	2
43	Subsequent Event Risk in Individuals With Established Coronary Heart Disease. Circulation Genomic and Precision Medicine, 2019, 12, e002470.	3.6	17
44	Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events. Circulation Genomic and Precision Medicine, 2019, 12, e002471.	3.6	22
45	Lipoprotein (a), arterial inflammation, and PCSK9 inhibition. European Heart Journal, 2019, 40, 2782-2784.	2.2	6
46	Protein-coding variants implicate novel genes related to lipid homeostasis contributing to body-fat distribution. Nature Genetics, 2019, 51, 452-469.	21.4	89
47	Inherited Chromosomally Integrated Human Herpesvirus 6 Demonstrates Tissue-Specific RNA Expression In Vivo That Correlates with an Increased Antibody Immune Response. Journal of Virology, 2019, 94, .	3.4	27
48	Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. New England Journal of Medicine, 2019, 381, 2497-2505.	27.0	1,696
49	Nuclear receptor gene polymorphisms and warfarin dose requirements in the Quebec Warfarin Cohort. Pharmacogenomics Journal, 2019, 19, 147-156.	2.0	5
50	ADCY9 (Adenylate Cyclase Type 9) Inactivation Protects From Atherosclerosis Only in the Absence of CETP (Cholesteryl Ester Transfer Protein). Circulation, 2018, 138, 1677-1692.	1.6	28
51	Rationale, design, and preliminary results of the Quebec Warfarin Cohort Study. Clinical Cardiology, 2018, 41, 576-585.	1.8	19
52	A Discrete Event Simulation Model to Assess the Economic Value of a Hypothetical Pharmacogenomics Test for Statin-Induced Myopathy in Patients Initiating a Statin in Secondary Cardiovascular Prevention. Molecular Diagnosis and Therapy, 2018, 22, 241-254.	3.8	12
53	Pharmacogenomics of blood lipid regulation. Pharmacogenomics, 2018, 19, 651-665.	1.3	3
54	A prospective study of the impact of AGTR1 A1166C on the effects of candesartan in patients with heart failure. Pharmacogenomics, 2018, 19, 599-612.	1.3	10

#	Article	IF	Citations
55	CYP3A4 genotype is associated with sildenafil concentrations in patients with heart failure with preserved ejection fraction. Pharmacogenomics Journal, 2018, 18, 232-237.	2.0	11
56	Identification of the genetic determinants responsible for retinal degeneration in families of Mexican descent. Ophthalmic Genetics, 2018, 39, 73-79.	1.2	10
57	Pharmacogenetic content of commercial genome-wide genotyping arrays. Pharmacogenomics, 2018, 19, 1159-1167.	1.3	8
58	Lineage restriction analyses in CHIP indicate myeloid bias for TET2 and multipotent stem cell origin for DNMT3A. Blood, 2018, 132, 277-280.	1.4	101
59	Sex, drugs, and heart failure: a sexâ€sensitive review of the evidence base behind current heart failure clinical guidelines. ESC Heart Failure, 2018, 5, 745-754.	3.1	36
60	Randomized Clinical Trial Needed to Confirm Whether Dalcetrapib Improves Outcomes for Specific ADCY9 Genotype. JAMA Cardiology, 2018, 3, 897.	6.1	5
61	Biomarkers of dementia in obstructive sleep apnea. Sleep Medicine Reviews, 2018, 42, 139-148.	8.5	63
62	Variants at the APOE/C1/C2/C4 Locus Modulate Cholesterol Efflux Capacity Independently of HighâĐensity Lipoprotein Cholesterol. Journal of the American Heart Association, 2018, 7, e009545.	3.7	25
63	Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity. Nature Genetics, 2018, 50, 26-41.	21.4	286
64	Abstract 624: Interactions Between Adenylate Cyclase Type 9 (ADCY9) and Cholesteryl Ester Transfer Protein (CETP) in Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, .	2.4	0
65	Opportunities for personalized approaches in heart failure. , 2018, , 3003-3005.		0
66	Methylomic changes during conversion to psychosis. Molecular Psychiatry, 2017, 22, 512-518.	7.9	56
67	A pharmacogenetic investigation of intravenous furosemide in decompensated heart failure: a meta-analysis of three clinical trials. Pharmacogenomics Journal, 2017, 17, 192-200.	2.0	11
68	CETP. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 396-400.	2.4	27
69	Systematic Evaluation of Pleiotropy Identifies 6 Further Loci Associated WithÂCoronary ArteryÂDisease. Journal of the American College of Cardiology, 2017, 69, 823-836.	2.8	214
70	Protein-altering and regulatory genetic variants near GATA4 implicated in bicuspid aortic valve. Nature Communications, 2017, 8, 15481.	12.8	90
71	Precision medicine to change the landscape of cardiovascular drug development. Expert Review of Precision Medicine and Drug Development, 2017, 2, 337-343.	0.7	0
72	Exome-wide association study of plasma lipids in >300,000 individuals. Nature Genetics, 2017, 49, 1758-1766.	21.4	470

#	Article	IF	Citations
73	Impact of Selection Bias on Estimation of Subsequent Event Risk. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	28
74	Pharmacogenetics of Lipid-Lowering Agents: an Update Review on Genotype-Dependent Effects of HDL-Targetingand Statin Therapies. Current Atherosclerosis Reports, 2017, 19, 43.	4.8	7
75	ABCA8 Regulates Cholesterol Efflux and High-Density Lipoprotein Cholesterol Levels. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 2147-2155.	2.4	55
76	Polygenic determinants in extremes of high-density lipoprotein cholesterol. Journal of Lipid Research, 2017, 58, 2162-2170.	4.2	49
77	CKing Precision in the Interpretation of Diagnostic Biomarkers. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	0
78	DNMT3A and TET2 dominate clonal hematopoiesis and demonstrate benign phenotypes and different genetic predispositions. Blood, 2017, 130, 753-762.	1.4	283
79	Older adults with heart failure treated with carvedilol, bisoprolol, or metoprolol tartrate: risk of mortality. Pharmacoepidemiology and Drug Safety, 2017, 26, 81-90.	1.9	4
80	Methylomic changes in individuals with psychosis, prenatally exposed to endocrine disrupting compounds: Lessons from diethylstilbestrol. PLoS ONE, 2017, 12, e0174783.	2.5	18
81	Diagnosis, Prevalence, Awareness, Treatment, Prevention, and Control of Hypertension in Cameroon: Protocol for a Systematic Review and Meta-Analysis of Clinic-Based and Community-Based Studies. JMIR Research Protocols, 2017, 6, e102.	1.0	6
82	Pillbox Use and INR Stability in a Prospective Cohort of New Warfarin Users. Journal of Managed Care & Specialty Pharmacy, 2016, 22, 676-684.	0.9	8
83	An expanded pharmacogenomics warfarin dosing table with utility in generalised dosing guidance. Thrombosis and Haemostasis, 2016, 116, 337-348.	3.4	15
84	Paternal Age Explains a Major Portion of De Novo Germline Mutation Rate Variability in Healthy Individuals. PLoS ONE, 2016, 11, e0164212.	2.5	41
85	Whole-genome sequencing in French Canadians from Quebec. Human Genetics, 2016, 135, 1213-1221.	3.8	16
86	Exome Genotyping Identifies Pleiotropic Variants Associated with Red Blood Cell Traits. American Journal of Human Genetics, 2016, 99, 8-21.	6.2	60
87	Meta-analysis of genome-wide association studies of HDL cholesterol response to statins. Journal of Medical Genetics, 2016, 53, 835-845.	3.2	28
88	Coding Variation inANGPTL4,LPL,andSVEP1and the Risk of Coronary Disease. New England Journal of Medicine, 2016, 374, 1134-1144.	27.0	427
89	DNA methylation signature of human fetal alcohol spectrum disorder. Epigenetics and Chromatin, 2016, 9, 25.	3.9	129
90	CYP3A4 Genotype is Associated with Sildenafil Concentrations in Patients with Heart Failure with Preserved Ejection Fraction. Journal of Cardiac Failure, 2016, 22, S11.	1.7	0

#	Article	IF	Citations
91	Maximal expected benefits from lowering cholesterol in primary prevention for a high-risk population. Current Medical Research and Opinion, 2016, 32, 1955-1958.	1.9	0
92	A model to assess the costâ€“effectiveness of pharmacogenomics tests in chronic heart failure: the case of ivabradine. Pharmacogenomics, 2016, 17, 1693-1706.	1.3	1
93	Genotype-Dependent Effects of Dalcetrapib on Cholesterol Efflux and Inflammation. Circulation: Cardiovascular Genetics, 2016, 9, 340-348.	5.1	59
94	Polygenic Versus Monogenic Causes of Hypercholesterolemia Ascertained Clinically. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 2439-2445.	2.4	174
95	genipe: an automated genome-wide imputation pipeline with automatic reporting and statistical tools. Bioinformatics, 2016, 32, 3661-3663.	4.1	22
96	Pharmacogenomic approaches to lipid-regulating trials. Current Opinion in Lipidology, 2016, 27, 557-562.	2.7	4
97	Platelet-Related Variants Identified by Exomechip Meta-analysis in 157,293 Individuals. American Journal of Human Genetics, 2016, 99, 40-55.	6.2	82
98	Pharmacogenomics to Revive Drug Development in Cardiovascular Disease. Cardiovascular Drugs and Therapy, 2016, 30, 59-64.	2.6	7
99	Resting heart rate as a predictor of aortic valve stenosis progression. International Journal of Cardiology, 2016, 204, 149-151.	1.7	11
100	Testing the role of predicted gene knockouts in human anthropometric trait variation. Human Molecular Genetics, 2016, 25, 2082-2092.	2.9	10
101	Avoidance of Vitamin Kâ€'Rich Foods Is Common among Warfarin Users and Translates into Lower Usual Vitamin K Intakes. Journal of the Academy of Nutrition and Dietetics, 2016, 116, 1000-1007.	0.8	9
102	Impact of regular physical activity on weekly warfarin dose requirement. Journal of Thrombosis and Thrombolysis, 2016, 41, 328-335.	2.1	8
103	Comparison of Sequencing Based CNV Discovery Methods Using Monozygotic Twin Quartets. PLoS ONE, 2015, 10, e0122287.	2.5	22
104	Mutation Burden of Rare Variants in Schizophrenia Candidate Genes. PLoS ONE, 2015, 10, e0128988.	2.5	17
105	Genetic markers associated with cutaneous adverse drug reactions to allopurinol: a systematic review. Pharmacogenomics, 2015, 16, 755-767.	1.3	23
106	Pharmacogenomic Determinants of the Cardiovascular Effects of Dalcetrapib. Circulation: Cardiovascular Genetics, 2015, 8, 372-382.	5.1	158
107	Cardiovascular pharmacogenomics; state of current knowledge and implementation in practice. International Journal of Cardiology, 2015, 184, 772-795.	1.7	15
108	A Pharmacogenetic Investigation of Intravenous Furosemide in Decompensated Heart Failure: A Meta-Analysis of 3 Clinical Trials. Journal of Cardiac Failure, 2015, 21, S16-S17.	1.7	0

#	Article	IF	Citations
109	Will personalized drugs for cardiovascular disease become an option? â€“ Defining â€˜Evidence-based personalized medicineâ€™ for its implementation and future use. Expert Opinion on Pharmacotherapy, 2015, 16, 2549-2552.	1.8	5
110	Calcium Signaling Pathway Genes RUNX2 and CACNA1C Are Associated With Calcific Aortic Valve Disease. Circulation: Cardiovascular Genetics, 2015, 8, 812-822.	5.1	51
111	ISDN2014_0418: DNA methylation changes in fetal alcohol spectrum disorder. International Journal of Developmental Neuroscience, 2015, 47, 126-126.	1.6	4
112	Higher frequency of genetic variants conferring increased risk for ADRs for commonly used drugs treating cancer, AIDS and tuberculosis in persons of African descent. Pharmacogenomics Journal, 2014, 14, 160-170.	2.0	29
113	Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. Nature Communications, 2014, 5, 5068.	12.8	216
114	Evaluation of Links Between High-Density Lipoprotein Genetics, Functionality, and Aortic Valve Stenosis Risk in Humans. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 457-462.	2.4	24
115	Lipoprotein(a) Levels, Genotype, and Incident Aortic Valve Stenosis. Circulation: Cardiovascular Genetics, 2014, 7, 304-310.	5.1	219
116	Validation of patientâ€reported warfarin dose in a prospective incident cohort study. Pharmacoepidemiology and Drug Safety, 2014, 23, 285-289.	1.9	4
117	Role of TPMT and COMT genetic variation in cisplatin-induced ototoxicity. Clinical Pharmacology and Therapeutics, 2014, 95, 253-253.	4.7	20
118	Development of a broad-based ADME panel for use in pharmacogenomic studies. Pharmacogenomics, 2014, 15, 1185-1195.	1.3	8
119	Novel Mutations in the Amyloid Precursor Protein Gene within Moroccan Patients with Alzheimer's Disease. Journal of Molecular Neuroscience, 2014, 53, 189-95.	2.3	5
120	Novel presenilin mutations within Moroccan patients with Early-Onset Alzheimerâ€™s Disease. Neuroscience, 2014, 269, 215-222.	2.3	15
121	Cuckoo search epistasis: a new method for exploring significant genetic interactions. Heredity, 2014, 112, 666-674.	2.6	48
122	CKMandLILRB5Are Associated With Serum Levels of Creatine Kinase. Circulation: Cardiovascular Genetics, 2014, 7, 880-886.	5.1	35
123	Modifiers of (CAG)n instability in Machadoâ€“Joseph disease (MJD/SCA3) transmissions: an association study with DNA replication, repair and recombination genes. Human Genetics, 2014, 133, 1311-1318.	3.8	33
124	Rare and low-frequency coding variants in CXCR2 and other genes are associated with hematological traits. Nature Genetics, 2014, 46, 629-634.	21.4	113
125	Comparison of genotype clustering tools with rare variants. BMC Bioinformatics, 2014, 15, 52.	2.6	7
126	Genetic Markers of Cisplatin-Induced Hearing Loss in Children. Clinical Pharmacology and Therapeutics, 2014, 96, 296-298.	4.7	7

#	Article	IF	Citations
127	Replication of TPMT and ABCC3 Genetic Variants Highly Associated With Cisplatin-Induced Hearing Loss in Children. Clinical Pharmacology and Therapeutics, 2013, 94, 243-251.	4.7	109
128	SRAP Polymorphisms Associated to Cell Wall Degradability in Lignified Stems of Alfalfa. Bioenergy Research, 2013, 6, 644-650.	3.9	5
129	Institutional Profile: The Beaulieu-Saucier UniversitÃ© de MontrÃ©al Pharmacogenomics Centre at the Montreal Heart Institute. Pharmacogenomics, 2013, 14, 131-136.	1.3	0
130	The Impact of Partial and Complete Loss-of-Function Mutations in Endothelial Lipase on High-Density Lipoprotein Levels and Functionality in Humans. Circulation: Cardiovascular Genetics, 2013, 6, 54-62.	5.1	53
131	pyGenClean: efficient tool for genetic data clean up before association testing. Bioinformatics, 2013, 29, 1704-1705.	4.1	16
132	Risk of congenital heart defects is influenced by genetic variation in folate metabolism. Cardiology in the Young, 2013, 23, 89-98.	0.8	24
133	Rare Copy Number Variants Contribute to Congenital Left-Sided Heart Disease. PLoS Genetics, 2012, 8, e1002903.	3.5	119
134	Pooled DNA Resequencing of 68 Myocardial Infarction Candidate Genes in French Canadians. Circulation: Cardiovascular Genetics, 2012, 5, 547-554.	5.1	10
135	Pharmacogenomic Prediction of Anthracycline-Induced Cardiotoxicity in Children. Journal of Clinical Oncology, 2012, 30, 1422-1428.	1.6	341
136	Genetic control of high density lipoprotein-cholesterol in AcB/BcA recombinant congenic strains of mice. Physiological Genomics, 2012, 44, 843-852.	2.3	3
137	A Novel PLP1 Mutation Further Expands the Clinical Heterogeneity at the Locus. Canadian Journal of Neurological Sciences, 2012, 39, 220-224.	0.5	3
138	Validation of warfarin pharmacogenetic algorithms in clinical practice. Pharmacogenomics, 2012, 13, 21-29.	1.3	25
139	PRKCB is associated with calcineurin inhibitor-induced renal dysfunction in heart transplant recipients. Pharmacogenetics and Genomics, 2012, 22, 336-343.	1.5	10
140	Tacrolimus-induced nephrotoxicity and genetic variability: A review. Annals of Transplantation, 2012, 17, 111-121.	0.9	53
141	Segregation of LIPG, CETP, and GALNT2 Mutations in Caucasian Families with Extremely High HDL Cholesterol. PLoS ONE, 2012, 7, e37437.	2.5	28
142	Predicting Statin Induced Muscle Toxicity. Journal of Clinical Lipidology, 2011, 5, 239-240.	1.5	0
143	Association between renal function and CYP3A5 genotype in heart transplant recipients treated with calcineurin inhibitors. Journal of Heart and Lung Transplantation, 2011, 30, 326-331.	0.6	19
144	Fetal Alcohol Spectrum Disorders: Gene-Environment Interactions, Predictive Biomarkers, and the Relationship Between Structural Alterations in the Brain and Functional Outcomes. Seminars in Pediatric Neurology, 2011, 18, 49-55.	2.0	50

#	Article	IF	Citations
145	Familial ventricular aneurysms and septal defects map to chromosome 10p15. European Heart Journal, 2011, 32, 568-573.	2.2	6
146	Design and rationale of a genetic cohort study on congenital cardiac disease: experiences from a multi-institutional platform in Quebec. Cardiology in the Young, 2011, 21, 654-664.	0.8	1
147	Genetics of bronchopulmonary dysplasia in the age of genomics. Current Opinion in Pediatrics, 2010, 22, 134-138.	2.0	49
148	Genome-Wide TDT Analysis in French-Canadian Families with Tourette Syndrome. Canadian Journal of Neurological Sciences, 2010, 37, 110-112.	0.5	6
149	Family Study of Restless Legs Syndrome in Quebec, Canada. Archives of Neurology, 2010, 67, 617-22.	4.5	63
150	Direct Measure of the De Novo Mutation Rate in Autism and Schizophrenia Cohorts. American Journal of Human Genetics, 2010, 87, 316-324.	6.2	222
151	Partitioning of copy-number genotypes in pedigrees. BMC Bioinformatics, 2010, 11, 226.	2.6	2
152	Positional cloning of a quantitative trait locus contributing to pain sensitivity: possible mediation by Tyrp1. Genes, Brain and Behavior, 2010, 9, 856-867.	2.2	5
153	A dominant-negative mutation in the TRESK potassium channel is linked to familial migraine with aura. Nature Medicine, 2010, 16, 1157-1160.	30.7	312
154	Testing for Gene-Gene Interaction with AMMI Models. Statistical Applications in Genetics and Molecular Biology, 2010, 9, Article 2.	0.6	7
155	De novo mutations in the gene encoding the synaptic scaffolding proteinSHANK3in patients ascertained for schizophrenia. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 7863-7868.	7.1	361
156	Genetic determinants of blood pressure reduction following potassium supplementation: and the candidates areâ€¦. Journal of Hypertension, 2010, 28, 668-670.	0.5	0
157	Novel mutations in the sacsin gene in ataxia patients from Maritime Canada. Journal of the Neurological Sciences, 2010, 288, 79-87.	0.6	18
158	Mutations in DCC Cause Congenital Mirror Movements. Science, 2010, 328, 592-592.	12.6	161
159	Genetic Studies. , 2010, , 113-120.		0
160	Application of Homozygosity Haplotype Analysis to Genetic Mapping with High-Density SNP Genotype Data. PLoS ONE, 2009, 4, e5280.	2.5	20
161	Different models and single-nucleotide polymorphisms signal the simulated weak gene-gene interaction for a quantitative trait using haplotype-based and mixed models testing. BMC Proceedings, 2009, 3, S77.	1.6	3
162	Application of principal component analysis to pharmacogenomic studies in Canada. Pharmacogenomics Journal, 2009, 9, 362-372.	2.0	23

#	Article	IF	Citations
163	Genetic predictors of depressive symptoms in cardiac patients. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2009, 150B, 381-388.	1.7	44
164	Autosomalâ€dominant locus for restless legs syndrome in Frenchâ€Canadians on chromosome 16p12.1. Movement Disorders, 2009, 24, 40-50.	3.9	44
165	Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nature Genetics, 2009, 41, 1345-1349.	21.4	287
166	Genetic Modulation of Brugada Syndrome by a Common Polymorphism. Journal of Cardiovascular Electrophysiology, 2009, 20, 1137-1141.	1.7	70
167	Association between cervical and intracranial dimensions and syringomyelia in the cavalier King Charles spaniel. Journal of Small Animal Practice, 2009, 50, 394-398.	1.2	28
168	Mutation in Pyrroline-5-Carboxylate Reductase 1 Gene in Families with Cutis Laxa Type 2. American Journal of Human Genetics, 2009, 85, 120-129.	6.2	81
169	A novel locus for idiopathic generalized epilepsy in Frenchâ€Canadian families maps to 10p11. American Journal of Medical Genetics, Part A, 2008, 146A, 578-584.	1.2	10
170	Ten reninâ€angiotensin systemâ€related gene polymorphisms in maximally treated Canadian Caucasian patients with heart failure. British Journal of Clinical Pharmacology, 2008, 65, 742-751.	2.4	46
171	CYP3A5*1/*3 Genetic Polymorphism Is Associated with Post Cardiac Transplant Renal Dysfunction in Patients Treated with Calcineurin Inhibitors. Journal of Cardiac Failure, 2008, 14, S3.	1.7	1
172	Effects of AGTR1 A1166C Gene Polymorphism in Patients with Heart Failure Treated with Candesartan. Annals of Pharmacotherapy, 2008, 42, 925-932.	1.9	33
173	Mutations in the calcium-related gene IL1RAPL1 are associated with autism. Human Molecular Genetics, 2008, 17, 3965-3974.	2.9	179
174	No evidence that skewing of X chromosome inactivation patterns is transmitted to offspring in humans. Journal of Clinical Investigation, 2008, 118, 333-341.	8.2	96
175	A survey of the personalized medicine landscape. Pharmacogenomics, 2008, 9, 819-823.	1.3	1
176	GÃ©nome QuÃ©bec & Montreal Heart Institute Pharmacogenomics Centre: aÂtranslational pharmacogenomics platform â€“ from R&D to the clinic. Pharmacogenomics, 2008, 9, 1391-1396.	1.3	2
177	Lamin A/C mutations associated with familial and sporadic cases of dilated cardiomyopathy in Koreans. Experimental and Molecular Medicine, 2007, 39, 114-120.	7.7	19
178	Additive Effects of Obesity and TCF7L2 Variants on Risk for Type 2 Diabetes Among Cardiac Patients. Diabetes Care, 2007, 30, 1621-1623.	8.6	10
179	The Genetics of Congenital Amusia (Tone Deafness): A Family-Aggregation Study. American Journal of Human Genetics, 2007, 81, 582-588.	6.2	156
180	Mutations in the UBIAD1 Gene, Encoding a Potential Prenyltransferase, Are Causal for Schnyder Crystalline Corneal Dystrophy. PLoS ONE, 2007, 2, e685.	2.5	111

#	Article	IF	Citations
181	Two-stage strategies to detect gene Ã— gene interactions in case-control data. BMC Proceedings, 2007, 1, S135.	1.6	2
182	Molecular genetic studies of DMT1 on 12q in Frenchâ€Canadian restless legs syndrome patients and families. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2007, 144B, 911-917.	1.7	29
183	Multistage designs in the genomic era: Providing balance in complex disease studies. Genetic Epidemiology, 2007, 31, S118-S123.	1.3	6
184	Loss-of-function genetic diseases and the concept of pharmaceutical targets. Nature Reviews Genetics, 2007, 8, 404-404.	16.3	0
185	Lossâ€ofâ€function mutations in the Na_v1.7 gene underlie congenital indifference to pain in multiple human populations. Clinical Genetics, 2007, 71, 311-319.	2.0	404
186	Syringomyelia in cavalier King Charles spaniels: the relationship between syrinx dimensions and pain. Journal of Small Animal Practice, 2007, 48, 432-436.	1.2	100
187	Bootstrap Inference with Neural-Network Modeling for Gene-Disease Association Testing. , 2006, , .		1
188	Common Genetic Vulnerability to Depressive Symptoms and Coronary Artery Disease: A Review and Development of Candidate Genes Related to Inflammation and Serotonin. Psychosomatic Medicine, 2006, 68, 187-200.	2.0	165
189	Human monogenic disorders â€" a source of novel drug targets. Nature Reviews Genetics, 2006, 7, 249-260.	16.3	81
190	Autism spectrum disorders associated with X chromosome markers in French-Canadian males. Molecular Psychiatry, 2006, 11, 206-213.	7.9	22
191	A novel autosomal dominant restless legs syndrome locus maps to chromosome 20p13. Neurology, 2006, 67, 900-901.	1.1	104
192	A new locus for autosomal dominant intracranial aneurysm, ANIB4, maps to chromosome 5p15.2-14.3. Journal of Medical Genetics, 2006, 43, e31-e31.	3.2	28
193	Chromosome 11-q24 region in Tourette syndrome: Association and linkage disequilibrium study in the French Canadian population. American Journal of Medical Genetics, Part A, 2005, 138A, 225-228.	1.2	9
194	Analysis of microsatellite markers and single nucleotide polymorphisms in candidate genes for susceptibility to bipolar affective disorder in the chromosome 12Q24.31 region. , 2005, 135B, 50-58.		33
195	A Variant in XPNPEP2 Is Associated with Angioedema Induced by Angiotensin Iâ€"Converting Enzyme Inhibitors. American Journal of Human Genetics, 2005, 77, 617-626.	6.2	113
196	Linkage mapping. , 2005, , .		2
197	Mutations in HFE2 cause iron overload in chromosome 1qâ€"linked juvenile hemochromatosis. Nature Genetics, 2004, 36, 77-82.	21.4	900
198	The 14q restless legs syndrome locus in the French Canadian population. Annals of Neurology, 2004, 55, 887-891.	5.3	71

#	Article	IF	Citations
199	A novel apoA-I mutation (L178P) leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery disease. Journal of the American College of Cardiology, 2004, 44, 1429-1435.	2.8	124
200	Identification of a Novel Gene (HSN2) Causing Hereditary Sensory and Autonomic Neuropathy Type II through the Study of Canadian Genetic Isolates. American Journal of Human Genetics, 2004, 74, 1064-1073.	6.2	133
201	Reproductive factors and ovarian cancer risk in Jewish BRCA1 and BRCA2 mutation carriers (United) Tj ETQq1 1 0.784314 rgBT /Overl	1.8	18
202	An ALS2 gene mutation causes hereditary spastic paraplegia in a Pakistani kindred. Annals of Neurology, 2003, 53, 144-145.	5.3	97
203	Oral Contraceptives and the Risk of Breast Cancer in BRCA1 and BRCA2 Mutation Carriers. Journal of the National Cancer Institute, 2002, 94, 1773-1779.	6.3	318
204	Fine mapping the candidate region for peripheral neuropathy with or without agenesis of the corpus callosum in the French Canadian population. European Journal of Human Genetics, 2002, 10, 406-412.	2.8	18
205	Mutant frizzled-4 disrupts retinal angiogenesis in familial exudative vitreoretinopathy. Nature Genetics, 2002, 32, 326-330.	21.4	409
206	Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives. Pharmacogenetics and Genomics, 2001, 11, 635-638.	5.7	44
207	Clouston hidrotic ectodermal dysplasia (HED): genetic homogeneity, presence of a founder effect in the French Canadian population and fine genetic mapping. European Journal of Human Genetics, 2000, 8, 372-380.	2.8	43
208	Genomic structure of the human GT334 (EHOC-1) gene mapping to 21q22.3. Gene, 1997, 198, 313-321.	2.2	4
209	An association study of <scp> ABCG2 </scp> rs2231142 on the concentrations of allopurinol and its metabolites. Clinical and Translational Science, 0, , .	3.1	7